Novo Nordisk to Acquire Ocedurenone from KBP Biosciences for ~$1.3B
Shots:
- Novo Nordisk will acquire ocedurenone (non-steroidal mineralocorticoid receptor antagonist) for ~$1.3B to treat uncontrolled hypertension with potential application in cardiovascular & kidney disease. The transaction is expected to close before the end of 2023
- The acquisition expands Novo Nordisk's drug portfolio in chronic disease. Ocedurenone is being studied in the P-III trial (CLARION-CKD) for uncontrolled hypertension & advanced CKD
- The P-III trials of ocedurenone are expected to initiate additional cardiovascular and kidney disease indications in the coming years. The (BLOCK-CKD) trial showed an improvement in systolic blood pressure from baseline to day 84 for stage 3b/4 CKD & uncontrolled hypertension with no reports of sev. hyperkalemia or acute kidney injury
Ref: Globenewswire | Image: Novo Nordisk
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.